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The U.S. Food, Drug, and Cosmetic Act, 21 U.S.C. § 301
et seq., creates a closed prescription drug manufacturing
and distribution system in the United States to preserve
a safe public drug supply, free from counterfeit and
other adulterated medications.' The U.S. Food and
Drug Administration (FDA), which is responsible for
the safety of the nation's drug supply, must approve
for marketing all prescription drugs distributed in the
United States. Those prescription drugs must bear FDA
approved labeling and packaging. 2 They also must be
manufactured at a domestic or foreign facility registered
with the FDA, which routinely inspects those plants,
whether foreign or domestic, for good manufacturing
practices. 3 Drug wholesalers and pharmacists must
be state licensed.' The interstate shipment of any
prescription drug (including importation and exportation)
that lacks required FDA approval is illegal.'
Prescription drugs are often manufactured in the United
States and then exported to foreign countries for sale
there. Once exported, drugs may only be reimported to
the original manufacturer in the United States. 6 While
the United States generally does not regulate prescription
drug prices, foreign countries may do so.7 For example,
in Canada, the Patented Medicine Prices Review Board
(PMPRB) "limits the prices set by manufacturers for all
patented medicines, new and existing, sold in Canada,
under prescription or over the counter, to ensure they are
not excessive."' As a result of these price regulations
and other factors, such as U.S. patent laws, prescription
drugs tend to be priced lower in foreign countries than
in the United States. 9
The PMPRB reported that manufacturers' prices for
patented drugs were 69 percent higher in the United
States as compared to Canada in 2001.10 A study
published in the Annals of Internal Medicine concluded,
"[b]rand name medications are often substantially less
expensive when purchased from Canadian internet
pharmacies instead of from major online U.S. drug
chain pharmacies.""
State and local governments facedwithrapidly increasing
prescription drug costs for their Medicaid and employee
benefit programs have considered controlling those
costs for themselves and their citizens by reimporting
U.S.-manufactured prescription drugs from Canada and
other countries. For example, Illinois has created the I-

SaveRx program.' 2 Minnesota created the Minnesota
RxConnect program earlier in this decade to help control
prescription drug costs.13 The FDA, however, opposed
both programs on safety grounds.14 Where other state
and local governments challenged the FDA's position in
court, the FDA has prevailed.'" Nevertheless, the FDA
has refrained from enforcement actions against similar
state-run prescription drug programs.' 6
Congress entered the fray in 2000 when it passed the
Medicine Equity and Drug Safety (MEDS) Act. The
law permitted the reimportation of prescription drugs
originally manufactured in the United States if the U.S.
Department of Health and Human Services (HHS)
Secretary determined that reimportation would be safe
and would significantly reduce costs. However, both
Donna Shalala, President Clinton's last HHS Secretary,
and Tommy Thompson, President Bush's first HHS
Secretary. declined to make those determinations.' 7
In2003, Congress replacedthe MEDSAct withaprovision
in the Medicare Prescription Drug and Modernization
Act, which authorizes the HHS Secretary to:
1. Promulgate regulations permitting pharmacists and
wholesalers to import drugs from Canada into the
United States, [and]
2. Grant to individuals, by regulation or on a case-bycase basis, a waiver of the prohibition of importation
of a prescription drug or device or class of prescription
drugs or devices under such circumstances as the
Secretary determines to be appropriate.'"
Similar to the MEDS Act, implementation of this law
remained contingent on the HHS Secretary certifying
to Congress that importation would be safe and costeffective.' 9 The Act also required HHS to prepare a
study on the issue for Congress. 20
Both Secretary Thompson and his successor, Michael
Leavitt, have declined to issue this certification. In a
2004 report, the Congressional Budget Office agreed
with HHS's position when it concluded that:
Permitting the importation of foreign-distributed
prescription drugs would produce at most a
miodest reduction ini prescription drug spending
in the United States. H.R. 2427, for example,
which would have permitted importation from

a broad set of industrialized countries, was estimated to reduce
total drug spending by $40 billion over 10 years, or by about 1
percent. Permitting importation only from Canada would produce
a negligible reduction in drug spending. 2'
When Vermont challenged HHS's inaction under the federal Administrative
Procedure Act, the federal district court sided with the HHS Secretary.22
Currently, a stalemate exists between the federal government and the state
governments that are operating drug importation programs without FDA
approval. Although the FDA has criticized these programs, it has not taken
any action to shut them down. In contrast, the FDA successfully used
the courts in 2003 to shut down an American-based business, Rx Depot,
which had been operating 85 storefronts in the United States to distribute
prescription drugs purchased from a Canadian pharmacy.2 3
Will Congress take further action to resolve this stalemate? At the conclusion
of its final session in October 2006, the 109th Congress did add a provision
to the Homeland Security Fiscal Year 2007 appropriations law that permits
individuals to import up to a 90-day supply of prescription drugs (excluding
controlled substances and biological products) purchased in Canada.24 This
action did not directly affect American mail-order and internet purchases
from Canadian pharmacies. However, also in October 2006, U.S. Customs
and Border Protection announced that it would no longer seize prescription
drugs that Canadian pharmacies send to U.S. residents.25 The Senate in
December 2006 approved the President's nomination of Dr. Andrew von
Eschenbach as FDA Commissioner.26 Senate action on that nomination
stalled for several months due to the FDA's opposition to prescription drug
27
importation, among other legislator concerns.
Time will tell whether the Democrat-controlled 110th Congress will break
the stalemate. On January 10, 2006, Senators Byron Dorgan (D-ND) and
Olympia Snowe (R-ME) as well as Representatives Rahm Emmanuel (DIL) and Jo Ann Emerson (R-MO) introduced bipartisan drug importation
legislation.28 If such legislation were to pass, the Administration's
opposition to the plan could lead to a Presidential veto. In any event, the
prescription drug manufacturers may hold the ultimate trump card because
they control the drug supply upon which re-importation is dependent.

